Endoxifen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go

Report scope. This 2026 Drug Asset Due Diligence Report evaluates Endoxifen as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.

Executive recommendation: CONDITIONAL GO

Endoxifen is a Small molecule drug associated with ER x PKC and a global highest development stage of Phase 2. The lead disclosed indication is Familial Testotoxicosis. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.

Decision memo

• Asset: Endoxifen
• Target: ER x PKC
• Lead indication: Familial Testotoxicosis
• Highest phase: Phase 2
• Matched trials: 19
• Matched result records: 11
• Matched asset deals: 1

Use PatSnap Life Sciences MCP servers to validate the Endoxifen diligence evidence.

1. Asset identity and development status

The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Endoxifen, the MCP profile identifies ER x PKC as the primary target context and Familial Testotoxicosis as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.

Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.

Use PatSnap Life Sciences MCP servers to validate the Endoxifen diligence evidence.

2. Clinical program: design and endpoint audit

The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.

Use PatSnap Life Sciences MCP servers to validate the Endoxifen diligence evidence.

3. Clinical readouts: what is known

A Phase 2 Trial of (Z)-endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+, HER2-, Breast Cancer (EVANGELINE)

Study: NCT05607004 (EVANGELINE, SABCS2025). Phase: Phase 2. Enrollment: 22. Published: 2025-12-09.

Ki67(achieving ≤10% at Week 4) = 86 %

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Study: NCT05068388 (KARISMA-Endoxifen, Company_Website). Phase: Phase 2. Enrollment: Not disclosed. Published: 2024-11-04.

PK = The mean endoxifen plasma concentration was 5.18 ng/mL in the 1 mg arm and 10.87 ng/mL in the 2 mg arm after one month of therapy. Plasma concentrations stayed the same at three and six months. | PK = The mean endoxifen plasma concentration was 5.18 ng/mL in the 1 mg arm and 10.87 ng/mL in the 2 mg arm after one month of therapy. Plasma concentrations stayed the same at three and six months.

Abstract CT205: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial

Study: NCT05607004 (EVANGELINE, AACR2024). Phase: Phase 2. Enrollment: 7. Published: 2024-04-05.

Css(median ENDX 28 day) = 263.6 ng/mL (range, 180.3 - 376.6)

Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery

Study: NCT03317405 (CTgov). Phase: Phase 1. Enrollment: 32. Published: 2023-06-13.

Number of Participants With Dermal Toxicity on Breast Skin at the Application Site = 4 Pts | Number of Participants With Dermal Toxicity on Breast Skin at the Application Site = 2 Pts

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

Study: NCT02311933 (PD7-06, CTgov). Phase: Phase 2. Enrollment: 81. Published: 2021-09-28.

PFS(Median) = 130 Day (95%CI, 76 - 138) | PFS(Median) = 42 Day (95%CI, 24 - 129)

Karma CREME-1: A Double-blind, Placebo-controlled, Three-armed, Pilot Study of the Effects, Safety and Tolerability of Topical Endoxifen in Women Within the Karma Cohort

Study: NCT04616430 (CREME, CTgov). Phase: Phase 2. Enrollment: 90. Published: 2021-06-18.

Change in Mammographic Breast Density At Study Exit(Mean) = -1.85 % | Change in Mammographic Breast Density At Study Exit(Mean) = -2.14 %

Abstract PD7-06: A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer

Study: NCT02311933 (AACR2020). Phase: Phase 2. Enrollment: 77. Published: 2020-02-15.

mPFS = 130 Day (95%CI, 76 - 138) | mPFS = 42 Day (95%CI, 24 - 129)

Phase I trial of z-endoxifen with estrogen receptor imaging in adults with advanced hormone receptor–positive solid tumors including desmoid and gynecologic tumors.

Study: NCT01273168 (ASCO 12018 | ASCO 22018). Phase: Phase 1. Enrollment: 40. Published: 2018-06-04.

AE(Grade 3/4) = hypertension (13%), hyponatremia (8%), hypophosphatemia (8%), neutropenia (8%), dehydration (5%), and elevated ALT (5%)

Evaluation of tumor and circulating cell free (cf) DNA mutations in women with hormone refractory metastatic breast cancer (MBC) enrolled in a phase I study of Z-endoxifen (MC093C).

Study: NCT01327781 (MC093C, ASCO2017). Phase: Phase 1. Enrollment: 41. Published: 2017-05-30.

Overall clinical benefit rate = 26.3 % (95%CI, 13.4 - 43.1)

Abstract PD2-03: Final results of a first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-Endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) (NCT01327781)

Study: NCT01327781 (phase I study of Z-Endoxifen hydrochloride, SABCS2016). Phase: Phase 1. Enrollment: 41. Published: 2016-02-15.

Endx Css = 3.6 μm

Abstract 4631: Pharmacokinetics and in vivo metabolism of Z-endoxifen: Results from two phase I studies in women with ER+ breast cancer, gynecologic malignancies and desmoids

Study: AACR2014. Phase: Phase 1. Enrollment: 44. Published: 2014-10-01.

Steady-state clearance = 6.2 L/h

For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.

Use PatSnap Life Sciences MCP servers to validate the Endoxifen diligence evidence.

4. Market and competitive position

The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Endoxifen against approved therapies and clinical competitors in Familial Testotoxicosis, including likely standards of care at the expected launch date.

Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.

Use PatSnap Life Sciences MCP servers to validate the Endoxifen diligence evidence.

5. Transaction precedent and economics

Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.

6. IP and freedom-to-operate screen

Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.

The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.

Use PatSnap Life Sciences MCP servers to validate the Endoxifen diligence evidence.

7. Principal risks and diligence gates

1. Identity risk: resolve all aliases, formulations, combinations, and owners.
2. Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
3. Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
4. IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
5. CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
6. Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
7. Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.

8. Final go/no-go memorandum

CONDITIONAL GO

Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.

Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.